Long-term follow up of patients proceeding to transplant using plerixafor mobilized stem cells and incidence of secondary myelodysplastic syndrome/AML

A. Deol, J. Abrams, A. Masood, Z. Al-Kadhimi, M. H. Abidi, L. Ayash, L. G. Lum, V. Ratanatharathorn, J. P. Uberti

Research output: Contribution to journalArticlepeer-review

23 Scopus citations

Abstract

We report the long-term follow up of 49 patients (pts) enrolled on plerixafor compassionate use protocol. Thirty-seven pts (76%) had failed one previous mobilization attempt, while 12 (24%) had failed two or more previous attempts. Using the combination of plerixafor and granulocyte colony-stimulating factor, we collected≥2.5 × 10 6 CD34+cells/kg in 33 pts (67%). Forty-three of the 49 pts proceeded to an auto-SCT (ASCT). The median days to WBC and platelet engraftment were 11 (range, 9-13 days) and 16 (range, 11-77 days) days post ASCT, respectively. The median WBC count, Hb and platelet counts 1 year after ASCT were 4.7 × 10 9 /L, 12.2 g/dL and 109 × 10 9 /L, respectively. With median follow up of 42 months (range <1-54 months), 21 pts had evidence of disease progression. Five pts developed myelodysplastic syndrome (MDS)/AML at median of 29 months post ASCT. The cumulative incidence of MDS/AML at 42 months was 17% (95% confidence interval, 6 to 32%). Development of secondary MDS/AML in pts proceeding to ASCT after plerixafor mobilization needs to be studied further in a larger cohort.

Original languageEnglish (US)
Pages (from-to)1112-1116
Number of pages5
JournalBone marrow transplantation
Volume48
Issue number8
DOIs
StatePublished - Aug 2013
Externally publishedYes

Keywords

  • Auto-SCT
  • Plerixafor
  • Secondary MDS/AML
  • Stem cell mobilization

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint

Dive into the research topics of 'Long-term follow up of patients proceeding to transplant using plerixafor mobilized stem cells and incidence of secondary myelodysplastic syndrome/AML'. Together they form a unique fingerprint.

Cite this